- Are you prone to experience respiratory problems including pneumonia?
Have you ever had lung infections that were difficult to treat?
Did you struggle to overcome a Covid infection?
If you answered yes to any of the above questions and currently experience Parkinsons symptoms, you want to provide protection again a pneumonia infection which is a leading cause of death among persons diagnosed with Parkinsons.
A new study offers a treatment found to offer respiratory support. The study evaluated a new photobiomodulation device – the Vielight RX-Plus – used as a treatment for 294 subjects experiencing COVID symptoms. Details of the study are reported below.
If you have confronted respiratory challenges in the past and decide to acquire the new Vielight RX-Plus device, there are two ways the company reduces the risk involved. First, they offer a 10% discount on all orders (coupon code healing4me). Second and most importantly, you are invited to use the device up to six months. If it does not offer the relief anticipated, you can return the device for an 80% refund.
Bottom line; Pneumonia is a serious health threat. The CODIV study results reported below suggest to me that the new photobiomodulation is a new treatment option for pneumonia worth serious consideration.
Vielight RX-Plus Study
This first-of-its-kind PBM major clinical trial (n=294) with the Vielight RX-Plus (Vielight X-Plus 4 equivalent) examined the efficacy of photobiomodulation (PBM) in treating acute COVID-19 infections.
The primary focus was on recovery speed in patients with moderate-to-severe symptoms. Patients with symptom durations of 0–7 days experienced significantly faster recovery when treated with PBM and standard care (SOC) compared to SOC alone. However, those with 8–12 days of symptoms did not show significant improvement.
Recruitment
Recruitment began in September 2020, with 701 adults who tested positive for COVID-19 assessed for eligibility. Of these, 407 did not meet the inclusion/exclusion criteria: 406 participants either had severity scores outside the required 4-7 range on the WURSS-44 scale or were outside the age range of 18-65, while one couldn’t complete forms in English. This left 294 eligible participants. Recruitment ended on July 5, 2021, due to the availability of monoclonal antibodies, declining interest, and sufficient numbers for statistical power, after which the datasets were locked.
Results summary
This study evaluated the effectiveness of photobiomodulation (PBM) therapy, specifically the Vielight RX Plus, in accelerating recovery from COVID-19 for non-hospitalized patients with moderate-to-severe symptoms. In patients experiencing symptoms for 0–7 days, PBM significantly reduced recovery time compared to standard of care (SOC) alone. However, in those with longer symptom durations (8–12 days), PBM did not produce a statistically significant improvement.
PBM was particularly effective in alleviating respiratory symptoms and reducing adverse effects like tachycardia and dysgeusia. It also contributed to a quicker recovery in specific symptoms such as headache, chest congestion, and body aches for patients in the 0–7 day symptom group. In contrast, the 8–12 day group showed slower recovery from fatigue and other energy-related symptoms, though they did experience milder symptom severity for some issues.
The study attributes the benefits of PBM to its anti-inflammatory effects, which have been linked to reduced cytokine levels in past research.
Robert Rodgers PhD
Founder 2004
Parkinsons Recovery